Dostarlimab, an anti-PD-1 monoclonal antibody, is being evaluated for safety in adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer in India. This study is significant as it targets a niche patient population that has limited treatment options following platinum-based therapies. The market for endometrial cancer therapeutics is growing, particularly in regions like India where the incidence is rising. GSK's positioning with dostarlimab could enhance its portfolio in immuno-oncology, especially given the increasing demand for personalized medicine. However, the competitive landscape includes other PD-1/PD-L1 inhibitors, necessitating a strong safety profile and differentiation in efficacy to capture market share.